This episode reviews risk based lipoprotein targets for atherosclerotic cardiovascular disease risk reduction. It highlights LDL-C, non-HDL-C, and apolipoprotein B as key parameters, with goals stratified by overall ASCVD risk category. It emphasizes the three tier framework of 100/130/90 for low risk, 70/100/70 for intermediate risk, and 55/85/55 for high or very high risk patients. It also covers primary versus secondary prevention targets, the role of apoB in refining atherogenic burden, especially in hypertriglyceridemia, and the importance of assigning risk first before applying lipid goals in clinical practice.